Physician profile
John J Tabor
NPI 1285894360
$567,357.03
in general payments reported to CMS, 2019-2025
36 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150K · 2020: $49K · 2021: $106K · 2022: $118K · 2023: $122K · 2024: $23K · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $89K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Travel and Lodging: $18K · Food and Beverage: $4,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $89,194.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,750.00 |
| Travel and Lodging | $17,714.47 |
| Food and Beverage | $4,793.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $564,614.52 | 2019-2024 | Da Vinci Surgical System, Da Vinci Sp |
| Medtronic, INC. | $315.87 | 2021-2025 | Closurerfs, Signia, Endoflip |
| Davol INC. | $283.48 | 2019-2025 | Arista Ah Flexitip, Phasix Mesh, Channel Drain |
| W. L. Gore & Associates, INC. | $255.11 | 2019-2020 | |
| Tas Medical, INC. | $218.48 | 2024 | |
| Ethicon US, LLC | $179.99 | 2020-2023 | Certus 140 |
| Becton, Dickinson and Company | $156.34 | 2023-2025 | Phasix Mesh |
| Pacira Pharmaceuticals Incorporated | $154.59 | 2020-2025 | Exparel |
| Covidien LP | $148.07 | 2019 | |
| Endo Pharmaceuticals INC. | $107.84 | 2019-2023 | Nascobal |
| Takeda Pharmaceuticals U.S.A., INC. | $82.94 | 2021-2023 | Gattex |
| Abbvie INC. | $78.68 | 2022 | |
| Stryker Corporation | $73.17 | 2023 | 1688, Spy-Phi System |
| Smith+Nephew, INC. | $63.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $61.71 | 2023 | Seglentis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $55.75 | 2024 | Irrisept |
| Histosonics, INC. | $53.89 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $46.40 | 2025 | |
| Aroa Biosurgery Incorporated | $43.27 | 2023 | |
| Dilon Technologies, INC. | $38.90 | 2025 | Hemoblast Bellows |
| Alcresta Therapeutics, INC. | $35.49 | 2023-2024 | Relizorb |
| Edwards Lifesciences Corporation | $29.29 | 2024 | |
| Integra Lifesciences Corporation | $28.54 | 2024 | Integra, Surgimend, Omnigraft |
| Tela Bio, INC. | $26.68 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Cook Biotech Incorporated | $23.24 | 2023 | Fortify Flowable |
| La Jolla Pharmaceutical Company | $21.12 | 2024 | Xerava |
| Aimmune Therapeutics, INC. | $20.60 | 2025 | Zenpep |
| Teleflex LLC | $18.31 | 2019 | |
| Endogastric Solutions, INC | $17.92 | 2021 | |
| Acacia Pharma INC | $17.92 | 2021 | |
| Novo Nordisk INC | $17.78 | 2023 | Wegovy |
| Sanara Medtech INC. | $14.84 | 2024 | Celleraterx |
| Coopersurgical, INC. | $13.73 | 2022 | |
| Lifenet Health | $13.61 | 2023 | |
| Mallinckrodt Enterprises LLC | $12.89 | 2019 | |
| Baxter Healthcare | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tabor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.